Taisho Pharmaceutical Holdings

January 07, 2019

Japanese biopharma rules mid-cap returns

Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?

December 19, 2018

In, out, in, out, Glaxo shakes consumer health about

Earlier this year Glaxosmithkline looked to be going all-in for consumer health domination, but today it moved to leave the space entirely and focus on the thing that pharma should do best.

October 10, 2018

Mid-cap investors see Eastern promise in the third quarter

Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…

July 04, 2018

Mid and small caps provide another rocky ride in the second quarter

Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.

July 04, 2018

Mid and small caps provide another rocky ride in the second quarter

Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.

March 20, 2017

ACC – Jardiance heart benefit looks like a class effect

March 20, 2017

ACC – Jardiance heart benefit looks like a class effect

September 12, 2016

Astra and Lexicon provide the good news in diabetes

April 06, 2016

Picking winners still possible in Q1

September 15, 2015

Some pharma senior citizens still work overtime

March 12, 2015

Big in Japan? As drug costs surge, diabetes and cancer win healthy premiums

Load More